Back to Business

Royalty Pharma expects modest return despite pelacarsen trial failure

Business September 4, 2026 at 11:08 PM

Royalty Pharma expects modest return despite pelacarsen trial failure

Investing.com

Read at Investing.com

More Stories

Okta CFO Brett Tighe sells $12.8 million in company shares

Okta CFO Brett Tighe sells $12.8 million in company shares

🇺🇸 Investing.com 57m ago

First Commonwealth Financial CFO sells $44,030 in stock

First Commonwealth Financial CFO sells $44,030 in stock

🇺🇸 Investing.com 58m ago

Kymera Therapeutics chief legal officer Adams disposes of $744k in KYMR stock

Kymera Therapeutics chief legal officer Adams disposes of $744k in KYMR stock

🇺🇸 Investing.com 58m ago

Your world briefing, in your pocket

AI-curated news from 12 countries and 10 languages — coming soon on iOS and Android.

Coming soon on App Store Coming soon on Google Play